Connect with us on the social channels
Press Releases
- DCprime Presents Interim Clinical Data of ADVANCE II Trial in Oral Presentation at ASH 2020 Meeting 7 December, 2020Phase II Data for DCprime’s Cell-based Cancer Relapse Vaccine Shows the Potential to Successfully Control Residual Disease as the Basis for a Prolonged Remission in AML Leiden, The Netherlands, December 7, 2020 – DCprime, the front-runner in the field of relapse vaccines, published interim results from its ongoing Phase II study (ADVANCE II, Clintrials.gov: NCT03697707) in …Read More
- DCprime Presents Preclinical Data at SITC 2020 Validating the Use of its Cell-based Cancer Relapse Vaccine in Ovarian Cancer 9 November, 2020Results demonstrate that the company’s lead vaccine candidate can direct a comprehensive immune response against ovarian tumor cells and induce the formation of memory T cells Leiden, The Netherlands, November 9, 2020 – DCprime, the front-runner in the field of relapse vaccines, today announced the presentation of preclinical results at the virtual 35th Annual Meeting of …Read More
- DCprime to Present Interim Clinical Data of ADVANCE II Trial in Oral Presentation at ASH 2020 Meeting 5 November, 2020Leiden, The Netherlands, November 5, 2020 – DCprime, the front-runner in the field of relapse vaccines, today announced the upcoming oral presentation of interim results from its ongoing Phase II clinical trial (ADVANCE II, Clintrials.gov: NCT03697707) at the virtual 62nd ASH Annual Meeting and Exposition on December 5, 2020. The Interim data on both primary …Read More
- DCprime and Glycotope Sign Licensing Agreement to Advance Program Combining Cancer Vaccination and Therapeutic Antibody Platforms 21 September, 2020Leiden, The Netherlands, and Berlin, Germany, September 21, 2020 – DCprime, the front-runner in the field of relapse vaccines, and Glycotope GmbH, a clinical-stage oncology/immuno-oncology company built on world-leading glycobiology expertise, today announced an expansion of their existing partnership through a new research collaboration and licensing agreement. Originally initiated in July 2018, the partnership combines DCprime’s …Read More
- DCprime and PCI Biotech Announce a Research Collaboration to Explore Novel Cancer Vaccination Concepts 1 September, 2020Leiden, The Netherlands and Oslo, Norway, September, 1st 2020 – DCprime, the front-runner in the field of relapse vaccines, and PCI Biotech (OSE: PCIB), a cancer focused biopharmaceutical company with a unique intracellular delivery technology via PhotoChemical Internalisation, today announced an extensive research collaboration. Within the collaboration, DCprime and PCI Biotech will combine their know-how and …Read More
- DCprime and University of Bergen Present Data on Novel Animal Model for Cancer Vaccine Research 12 June, 2020Presentation at EHA Congress reviews development of a humanized immunocompetent mouse model to study DCP-001 as a vaccine for leukemia Leiden, The Netherlands, June 12, 2020 –DCprime, the front-runner in the field of relapse vaccines, in collaboration with the University of Bergen, today announced the presentation of a novel preclinical animal model tailored for cancer vaccine …Read More
- DCprime Extends International Roll-out of DCP-001 Into the United States 13 May, 2020Opening of IND follows approval to study DCP-001 in multiple European countries Leiden, The Netherlands, May 13, 2020 –DCprime, the front-runner in the field of relapse vaccines, today announced that the U.S. Food and Drug Administration (FDA) has accepted the company’s Investigational New Drug (IND) application for DCP-001, an allogeneic cancer relapse vaccine currently being evaluated …Read More
- DCprime Receives US FDA Orphan Drug Designation for DCP-001 in Acute Myeloid Leukemia 5 December, 2019Leiden, The Netherlands, December 05, 2019 –DCprime, the front-runner in the field of relapse vaccines, today announced that the United States Food and Drug Administration (FDA) has granted Orphan Drug Designation to DCP-001 for the treatment of acute myeloid leukemia (AML). DCP-001 is a cell-based vaccine addressing blood cancers with a high risk of relapse …Read More
- DCprime to Present Long-term Follow-up and Survival Data for Lead Relapse Vaccine Candidate DCP-001 in High-Risk AML and MDS Patients 13 November, 2019Presentation at ASH Annual Meeting Shows Potential to Prolong Relapse-Free Survival and Overall Survival Using an Allogeneic Cell-based Vaccine in the Post-Remission Setting Leiden, The Netherlands, November 13, 2019 –DCprime, the front-runner in the field of relapse vaccines, today announced the presentation of updated clinical results for its lead product DCP-001 at the upcoming 61st Annual …Read More
- DCprime Presents Preclinical Data on Novel Vaccination Concept Using the DCOne® Cell Line in Solid Tumour Models 6 November, 2019Presentation at SITC Shows Potential to Flag Solid Tumours as a Target for the Immune System to Attack Using the Company’s DCOne® Cell Vaccine Loaded with a Foreign Antigen Leiden, The Netherlands, November 6, 2019 –DCprime, the front-runner in the field of relapse vaccines, today announced the presentation of preclinical proof-of-concept results at the 34th Annual …Read More
DCprime Receives US FDA Orphan Drug Designation for DCP-001 in Acute Myeloid Leukemia
Leiden, The Netherlands, December 05, 2019 –DCprime, the front-runner in the field of relapse vaccines, today announced that the United States Food and Drug Administration (FDA) has granted Orphan Drug Designation to DCP-001 for the treatment of acute myeloid leukemia (AML). DCP-001 is a cell-based vaccine addressing blood cancers with
DCprime to Present Long-term Follow-up and Survival Data for Lead Relapse Vaccine Candidate DCP-001 in High-Risk AML and MDS Patients
Presentation at ASH Annual Meeting Shows Potential to Prolong Relapse-Free Survival and Overall Survival Using an Allogeneic Cell-based Vaccine in the Post-Remission Setting Leiden, The Netherlands, November 13, 2019 –DCprime, the front-runner in the field of relapse vaccines, today announced the presentation of updated clinical results for its lead product
DCprime Presents Preclinical Data on Novel Vaccination Concept Using the DCOne® Cell Line in Solid Tumour Models
Presentation at SITC Shows Potential to Flag Solid Tumours as a Target for the Immune System to Attack Using the Company’s DCOne® Cell Vaccine Loaded with a Foreign Antigen Leiden, The Netherlands, November 6, 2019 –DCprime, the front-runner in the field of relapse vaccines, today announced the presentation of preclinical
DCprime Initiates Research Collaboration with the University Medical Center of Groningen on Relapse Vaccine Approach for Ovarian Cancer
Leiden, The Netherlands, September 10, 2019 – DCprime, the front-runner in the field of relapse vaccines, today announced the initiation of a research collaboration with the Department of Obstetrics and Gynecology at the University Medical Center of Groningen (UMCG) lead by Professor Hans Nijman MD PhD. The purpose of the
DCprime Presents Comprehensive Preclinical Results Supporting Lead Clinical Candidate DCP-001
Leiden, The Netherlands, May 14, 2019 – DCprime, the front-runner in the field of relapse vaccines, today announced presentations of additional preclinical data sets for its lead program, DCP-001, at the 7th CCBIO Annual Symposium and the 2019 CIMT Annual Meeting. The data supports key product characteristics and sheds additional
DCprime Strengthens Supervisory Board with the Additions of Andrea van Elsas and Hans Preusting
Leiden, The Netherlands, April 25, 2019 – DCprime, the front-runner in the field of relapse vaccines, today announced the appointment of two highly-experienced industry veterans, Andrea van Elsas, Ph.D. and Hans Preusting, Ph.D., M.B.A, to its Supervisory Board. The newest members complement the existing Board, with Dharminder Chahal remaining Chairman
DCprime and Radboudumc to collaborate
Leiden, The Netherlands and Nijmegen, The Netherlands, March 2019– DCprime and Radboudumc announce that they will collaborate as part of a public-private consortium supported by The Dutch Top Sector Life Sciences and Health, represented by Stichting Life Sciences Health – TKI, also acting under its trade name Health~Holland, under the